Guardant Health (GH) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
The meeting was called to order shortly after 9:30 A.M. Pacific Time and conducted virtually to maximize accessibility for stockholders.
The agenda and rules of conduct were made available on the meeting web portal, with procedures for voting and asking questions clearly outlined.
The formal portion of the meeting was conducted first, followed by a Q&A session for stockholders.
Board and executive committee updates
The Chairperson, Helmy Eltoukhy, presided over the meeting, with participation from the full Board of Directors and designated proxies.
Representatives from Deloitte & Touche LLP (auditors) and Gunderson Dettmer (legal counsel) were present.
Shareholder proposals
Four proposals were presented: election of Class II directors, ratification of the independent auditor, advisory approval of executive compensation, and advisory approval of the frequency of future votes on executive compensation.
Latest events from Guardant Health
- Q2 2026 revenue up 44% to $335M; guidance raised as Shield and oncology volumes surged.GH
Q2 202630 Jul 2026 - Multi-cancer early detection is poised to transform cancer care, reducing mortality and costs.GH
7th Annual Healthcare Symposium14 Jul 2026 - 2028 revenue target raised to ~$2.2B, with accelerated breakeven and major product launches.GH
Investor Day 20259 Jul 2026 - Q3 revenue up 34% to $191.5M; Shield launch, ASP gains, and raised guidance highlight growth.GH
Q3 20248 Jul 2026 - Strong growth and innovation, with regulatory and commercial catalysts set to drive 2026 performance.GH
TD Cowen 46th Annual Health Care Conference8 Jul 2026 - 2025 revenue up 33% year-over-year, with robust outlook and innovation driving 2026 growth.GH
Q4 20258 Jul 2026 - 31% revenue growth, margin gains, and Shield's FDA approval drive strong 2025 outlook.GH
Q4 20248 Jul 2026 - All proposals passed, directors elected, and no stockholder questions were raised.GH
AGM 20248 Jul 2026 - Q2 revenue up 29% to $177.2M; Shield test FDA approved; 2024 guidance raised to $690–$700M.GH
Q2 20248 Jul 2026